Background illustration for clinical trials search

Paid Clinical Trials Augusta

Discover 151 paid clinical trials in Augusta, Maine. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

for
Atrial Fibrillation, Stroke, Bleeding
Location: Portland ME, Lebanon NH, Boston MA, Burlington VT,
Sponsor: Icahn School of Medicine at Mount Sinai

Sex: All

Age: 18+

Code: NCT04045665

Phase3, Recruiting

(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000

for
Epiretinal Membrane, Dry Age Related Macular Degeneration,
Location: Portland ME, Kansas City MO, Fort Lauderdale FL,
Sponsor: Carl Zeiss Meditec-Dublin CoCe

Sex: All

Age: 18+

Code: NCT07680244

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

for
Non Small Cell Lung Cancer
Location: Westbrook ME, Greenfield Park, Montreal, Stony Brook NY,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06312137

Phase3, Recruiting

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

for
Non-small Cell Lung Cancer
Location: Westbrook ME, Albany NY, Farmington CT, Stamford CT,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07190248

Phase3, Recruiting

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

for
Breast Neoplasms, Triple Negative Breast Neoplasms,
Location: Westbrook ME, Sherbrooke, Quebec, Trois-Rivieres,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06966700

Phase3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

for
Non-small Cell Lung Cancer (NSCLC)
Location: Westbrook ME, Mississauga, Brampton, Rochester MN,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06170788

Phase3, Recruiting

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

for
Chronic Lymphocytic Leukemia (CLL),
Location: Scarborough ME, Boston MA, South Weymouth MA
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT05168930

Phase2, Recruiting

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

for
Renal Cell Carcinoma
Location: Westbrook ME, Baltimore MD, Charlotte NC, Knoxville TN,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07227402

Phase3, Recruiting

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Scarborough ME, Boston MA
Sponsor: Inhye Ahn

Sex: All

Age: 18+

Code: NCT06333262

Phase2, Recruiting

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

for
HER2-positive Breast Cancer, Breast Cancer
Location: Scarborough ME, New York NY, Camillus NY,
Sponsor: Jazz Pharmaceuticals

Sex: All

Age: 18+

Code: NCT07102381

Phase2, Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

for
Triple Negative Breast Cancer
Location: Scarborough ME, Methuen MA, Boston MA,
Sponsor: Gilead Sciences

Sex: All

Age: 18+

Code: NCT05633654

Phase3, Recruiting

ATEMPT 2.0: Adjuvant T-DM1 vs TH

for
Breast Cancer, HER2-positive Breast Cancer
Location: Scarborough ME, Brewer ME, Portsmouth NH, Concord NH,
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT04893109

Phase2, Recruiting

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

for
Breast Cancer
Location: Portland ME, Albany NY, Waterbury CT, Mount Kisco NY,
Sponsor: Agendia

Sex: All

Age: 18+

Code: NCT03053193

Recruiting

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

for
Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR),
Location: Westbrook ME, Toronto, Indianapolis IN, Zion IL,
Sponsor: Amgen

Sex: All

Age: 18 - 70+

Code: NCT07403721

Phase1, Recruiting

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

for
Breast Neoplasms
Location: Westbrook ME, Burlington MA, New York NY,
Sponsor: BioNTech SE

Sex: All

Age: 18+

Code: NCT07173751

Phase3, Recruiting

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

for
Metastatic Gastric Adenocarcinoma,
Location: Westbrook ME, Florham Park NJ, Flemington NJ,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT07043400

Phase3, Recruiting

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

for
Carcinoma, Non-Small-Cell Lung
Location: Westbrook ME, Burlington VT, Worcester MA, Hartford CT,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT06890598

Phase3, Recruiting

The THOR IDE Study

for
Peripheral Artery Disease, Peripheral Artery Stenosis,
Location: Portland ME, Leominster MA, Providence RI,
Sponsor: Philips Clinical & Medical Affairs Global

Sex: All

Age: 18+

Code: NCT05916950

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

for
Non-small Cell Lung Cancer
Location: Scarborough ME, Saint John, Montreal, West Haven CT,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT06692738

Phase3, Recruiting

GLP-1R Actions on Muscle and the Skeleton

for
Musculoskeletal Abnormalities, Obesity, Sarcopenic Obesity,
Location: Scarborough ME
Sponsor: Pennington Biomedical Research Center

Sex: All

Age: 18 - 50

Code: NCT07154719

Recruiting